Egyptian MTA and Biodentine versus Calcium Hydroxide for indirect pulp capping in permanent teeth
Comparative Analysis of Egyptian MTA, Biodentine, and Calcium Hydroxide as Indirect Pulp Capping Materials in Permanent Teeth. (A 6m Randomized Clinical Trial)
This will test whether Egyptian MTA or Biodentine work better than calcium hydroxide for indirect pulp capping in adults with deep cavities to help keep the tooth's pulp healthy.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 35 (estimated) |
| Ages | 22 Years to 45 Years |
| Sex | All |
| Sponsor | Cairo University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT06683833 on ClinicalTrials.gov |
What this trial studies
This interventional Phase 4 study compares three indirect pulp capping materials—Egyptian mineral trioxide aggregate (MTA), Biodentine, and calcium hydroxide—in adult permanent teeth with deep carious lesions. Eligible patients (aged 22–45, vital teeth, good general health and oral hygiene) receive indirect pulp capping with one of the materials and are followed for clinical outcomes and patient-reported satisfaction. Outcomes include pulp vitality, formation of reparative dentin, restoration success, and any adverse reactions measured at scheduled clinical and radiographic follow-ups. Standard dental IPC procedures are used and data will be collected to directly compare material performance in routine clinical settings.
Who should consider this trial
Good fit: Adults aged 22–45 with vital permanent teeth affected by deep carious lesions, who are in good general health, maintain good oral hygiene, and can attend follow-up visits.
Not a fit: Patients with non-vital or extensively compromised teeth, systemic diseases, poor oral hygiene, known allergies to the materials, or who regularly use analgesics that mask pain are unlikely to benefit.
Why it matters
Potential benefit: If successful, the better-performing material could preserve pulp health more reliably, reduce the need for root canal treatment, and improve long-term tooth survival.
How similar studies have performed: Previous clinical work has generally shown MTA and Biodentine to perform as well as or better than calcium hydroxide for vital pulp therapies, so this study builds on established evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients aged 22: 45 years old. * Males or females. * Patients with vital teeth with deep carious lesions. * Patients in good general health. * Good oral hygiene. * Co-operative patients who show interest to participate in the study. Exclusion Criteria: * Patients with systemic diseases. * Patients with known allergic or adverse reaction to the tested materials. * Patients with bad oral hygiene. * Patient who frequently use analgesic or any drugs that could mask the pain.
Where this trial is running
Cairo
- El Monira General Hospital — Cairo, Egypt (Recruiting)
Study contacts
- Study coordinator: Alaa T Elsorogy, Master's candidate
- Email: alaa.elsorogy@dentistry.cu.edu.eg
- Phone: 0020201010009938
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.